Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Akebia Therapeutics clinical trials
The registry lists 51 studies whose lead sponsor is Akebia Therapeutics or one of 1 company grouped under it. 3 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 6, 2026.
Keep track of what changes. Save the Akebia Therapeutics studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Akebia Therapeutics.
- Akebia Therapeutics37 studiesSame company
Something wrong?
- Keryx Biopharmaceuticals14 studies →Acquired — became part of Akebia Therapeutics, Dec 12, 2018 · source ↗
Something wrong?
Focus areas
Conditions Akebia Therapeutics leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 51. Browse all 51 →
- SAD and MAD Study of AKB-9090 in Healthy Adult ParticipantsRecruitingNCT07429006Phase 1
- A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3GRecruitingNCT06419205Phase 2
- A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)RecruitingNCT07268638Phase 2
- To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center HemodialysisCompletedNCT06901505Phase 3
- Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney DiseaseSuspendedNCT04523727Phase 3
Sponsor listed in the registry: Keryx Biopharmaceuticals · First submitted after Keryx Biopharmaceuticals became part of Akebia Therapeutics
- Study to Evaluate the Safety and Tolerability of KRX-0502 (Ferric Citrate) in Children With Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney DiseaseWithdrawnNCT04649411Phase 3
Sponsor listed in the registry: Keryx Biopharmaceuticals · First submitted after Keryx Biopharmaceuticals became part of Akebia Therapeutics
- Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating AgentsWithdrawnNCT05082584Phase 3
- Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney DiseaseWithdrawnNCT05082571Phase 3
- Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)CompletedNCT04313153Phase 3
- Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis SubjectsCompletedNCT04707768Phase 3
- Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin AlfaCompletedNCT03799627Phase 2
- A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by AlbuminuriaCompletedNCT03217591Phase 2
- A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)CompletedNCT03254485Phase 2
- 20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and AnemiaCompletedNCT01906489Phase 2
- Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)CompletedNCT02865850Phase 3
- 42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and AnemiaCompletedNCT01381094Phase 2
- Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and AnemiaCompletedNCT01235936Phase 2
- 16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic HemodialysisCompletedNCT02260193Phase 2
- Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4CompletedNCT04707573Phase 2
- Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)CompletedNCT02892149Phase 3
- Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)CompletedNCT02680574Phase 3
- Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney DiseaseCompletedNCT02648347Phase 3
- Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Dialysis-Dependent Chronic Kidney Disease (DD-CKD)CompletedNCT03054350Phase 2
- Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)CompletedNCT03054337Phase 2
- Effect of Sulodexide in Overt Diabetic NephropathyTerminatedNCT00130312Phase 4
Sponsor listed in the registry: Keryx Biopharmaceuticals · First submitted before Keryx Biopharmaceuticals became part of Akebia Therapeutics
- KRX-0502 (Ferric Citrate) in Subjects With NDD-CKD and IDA (The COMPASS Trial)CompletedNCT03236246Phase 4
Sponsor listed in the registry: Keryx Biopharmaceuticals · First submitted before Keryx Biopharmaceuticals became part of Akebia Therapeutics
- Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating AgentsTerminatedNCT03140722Phase 2
- Study in Healthy Adult Subjects to Assess the Effect of Phosphate Binders on the Pharmacokinetics of a Single Dose of VadadustatCompletedNCT04299633Phase 1
- Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney DiseaseCompletedNCT03992066Phase 1
- A Study in Evaluating Bioequivalence Between Test and Reference Formulations of Vadadustat Tablets in Healthy AdultsCompletedNCT03639155Phase 1
- A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic FunctionCompletedNCT03799848Phase 1
- Drug-Drug Interaction Study of Vadadustat With Cyclosporine, Probenecid and RifampinCompletedNCT03801746Phase 1
- Drug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and FurosemideCompletedNCT03801759Phase 1
- Study to Evaluate the Effect of Rabeprazole on the Pharmacokinetics of VadadustatCompletedNCT03789032Phase 1
- A Study in Evaluating Bioequivalence of Test and Reference Vadadustat 450 MG and 150 MG Tablets and to Determine Food Effect on the 450 MG TabletCompletedNCT03657290Phase 1
- Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and SimvastatinCompletedNCT03801733Phase 1
- Effects of Ferrous Sulfate on the Pharmacokinetics of AKB-6548CompletedNCT02327546Phase 1
- Relative Bioavailability of Two Formulations of AKB-6548 and the Food Effect of a New Tablet in Healthy Adult SubjectsCompletedNCT02412449Phase 1
- Effect of AKB-6548 on the Pharmacokinetics of CelecoxibCompletedNCT02502500Phase 1
- Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy VolunteersCompletedNCT02062203Phase 1
- Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD)WithdrawnNCT03242967Phase 3
- A Pilot Study of KRX-0502 (Ferric Citrate, Administered Without Food, in Treating Iron-deficiency AnemiaCompletedNCT02128074Phase 2
Sponsor listed in the registry: Keryx Biopharmaceuticals · First submitted before Keryx Biopharmaceuticals became part of Akebia Therapeutics
- Effect of Sulodexide in Early Diabetic NephropathyCompletedNCT00130208Phase 3
Sponsor listed in the registry: Keryx Biopharmaceuticals · First submitted before Keryx Biopharmaceuticals became part of Akebia Therapeutics
- KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKDCompletedNCT02268994Phase 3
Sponsor listed in the registry: Keryx Biopharmaceuticals · First submitted before Keryx Biopharmaceuticals became part of Akebia Therapeutics
- Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on DialysisCompletedNCT01736397Phase 2
Sponsor listed in the registry: Keryx Biopharmaceuticals · First submitted before Keryx Biopharmaceuticals became part of Akebia Therapeutics
- A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)CompletedNCT00648167Phase 2
Sponsor listed in the registry: Keryx Biopharmaceuticals · First submitted before Keryx Biopharmaceuticals became part of Akebia Therapeutics
- Open Label Tolerability and Safety Study of KRX-101 in Australia, New Zealand, and Hong KongTerminatedNCT00462202Phase 3
Sponsor listed in the registry: Keryx Biopharmaceuticals · First submitted before Keryx Biopharmaceuticals became part of Akebia Therapeutics
- A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on DialysisCompletedNCT01554982Phase 3
Sponsor listed in the registry: Keryx Biopharmaceuticals · First submitted before Keryx Biopharmaceuticals became part of Akebia Therapeutics
- A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on DialysisCompletedNCT01191255Phase 3
Sponsor listed in the registry: Keryx Biopharmaceuticals · First submitted before Keryx Biopharmaceuticals became part of Akebia Therapeutics
- Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal DiseaseCompletedNCT00967993
Sponsor listed in the registry: Keryx Biopharmaceuticals · First submitted before Keryx Biopharmaceuticals became part of Akebia Therapeutics